Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond

被引:87
作者
Becker, JC [1 ]
Domschke, W [1 ]
Pohle, T [1 ]
机构
[1] Univ Munster, Dept Med B, D-48129 Munster, Germany
关键词
aspirin; COX/5-LOX; H; pylori; haeme-oxygenase; NO-NSAID; PPI;
D O I
10.1111/j.1365-2125.2004.02198.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gastrointestinal (Gl) toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) is still an important medical and socio-economic problem-despite recent pharmaceutical advances. To prevent NSAID-induced gastropathy, three strategies are followed in clinical routine: (i) coprescription of a gastroprotective drug, (ii) use of selective COX-2 inhibitors, and (iii) eradication of Helicobacter pylori. Proton pump inhibitors are the comedication of choice as they effectively reduce gastrointestinal adverse events of NSAIDs and are safe even in long-term use. Co-medication with vitamin C has only been little studied in the prevention of N SAID-induced gastropathy. Apart from scavenging free radicals it is able to induce haeme-oxgenase 1 in gastric cells, a protective enzyme with antioxidant and vasodilative properties. Final results of the celecoxib outcome study (CLASS study) attenuated the initial enthusiasm about the Gl safety of selective COX-2 inhibitors, especially in patients concomitantly taking aspirin for cardiovascular prophylaxis. Helicobacter pylori increases the risk for ulcers particularly in NSAID-naive patients and therefore eradication is recommended prior to long-term NSAID therapy at least in patients at high risk. New classes of COX-inhibitors are currently evaluated in clinical studies with very promising results: NSAIDs combined with a nitric oxide releasing moiety (NO-NSAID) and dual inhibitors of COX and 5-LOX. These drugs offer extended anti-inflammatory potency while sparing gastric mucosa.
引用
收藏
页码:587 / 600
页数:14
相关论文
共 126 条
  • [71] NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors
    Micklewright, R
    Lane, S
    Linley, W
    McQuade, C
    Thompson, F
    Maskrey, N
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (03) : 321 - 332
  • [72] Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
    Mizuno, H
    Sakamoto, C
    Matsuda, K
    Wada, K
    Uchida, T
    Noguchi, H
    Akamatsu, T
    Kasuga, M
    [J]. GASTROENTEROLOGY, 1997, 112 (02) : 387 - 397
  • [73] *NAT I CLIN EXC, 2001, TECHNOLOGY APPRAISAL, V27, P1
  • [74] Nefesoglu FZ, 1998, INT J CLIN PHARM TH, V36, P549
  • [75] VITAMIN-C IN THE HUMAN STOMACH - RELATION TO GASTRIC PH, GASTRODUODENAL DISEASE, AND POSSIBLE SOURCES
    OCONNOR, HJ
    SCHORAH, CJ
    HABIBZEDAH, N
    AXON, ATR
    COCKEL, R
    [J]. GUT, 1989, 30 (04) : 436 - 442
  • [76] Ofman JJ, 2002, J RHEUMATOL, V29, P804
  • [77] Palmer BF, 1995, J INVEST MED, V43, P516
  • [78] Palmer RH, 2002, GASTROENTEROLOGY, V122, pA54
  • [79] PAVELKA K, 2003, ANN RHEUM DIS, P62
  • [80] Role of cyclooxygenase-2 in gastric mucosal defense
    Peskar, BM
    Maricic, N
    Gretzer, B
    Schuligoi, R
    Schmassmann, A
    [J]. LIFE SCIENCES, 2001, 69 (25-26) : 2993 - 3003